Literature DB >> 837378

In vitro and in vivo cytotoxicity of adriamycin and daunomycin for murine macrophages.

A Mantovani.   

Abstract

In virto exposure of murine lymphoma cells to adriamycin and daunomycin (DM) for 24 hr resulted in comparable cytotoxicity as assessed by viable cell counts and inhibition of DNA synthesis. The spontaneous DNA synthesis of spleen lymphocytes in vitro was also equally affected by the two agents. However, when the in vitro effects of the two drugs on macrophage monolayers were investigated, DM was found to be at least four times more toxic than AM. In vivo-administered DM was more suppressive than AM of Corynebacterium parvum-induced spleen macrophage cytotoxicity. The fact that DM is less effective than AM as a cancer chemotherapeutic agent in vivo may actually be due to the greater destruction of macrophages by DM and a resultant reduction in the contribution of host immunity to the anti-tumor action.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 837378

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Cancer chemotherapeutics as immunomodulators.

Authors:  F Spreafico; A Vecchi; F Colotta; A Montovani
Journal:  Springer Semin Immunopathol       Date:  1985

2.  Chemotherapy, a double agent in respect of immune functions.

Authors:  G Mathé
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

3.  Biological activities of rubidazone.

Authors:  R Maral
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

4.  Analysis of therapeutic effect in experimental chemoimmunotherapy for rat ascites tumor.

Authors:  T Ogura; O Shinzato; M Sakatani; H Shindo; M Namba; S Kishimoto; Y Yamamura
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

5.  Microfluidic technique to measure intratumoral transport and calculate drug efficacy shows that binding is essential for doxorubicin and release hampers Doxil.

Authors:  Bhushan J Toley; Zachary G Tropeano Lovatt; Josephine L Harrington; Neil S Forbes
Journal:  Integr Biol (Camb)       Date:  2013-09       Impact factor: 2.192

6.  The synergistic tumoricidal activity of anticancer drugs and oxidative burst-triggered macrophages.

Authors:  S Marcovitch; Y Keisari
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

7.  Adriamycin-induced activation of NK activity may initially involve LAF production.

Authors:  S A Cohen; D Salazar; J Wicher
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

8.  Cytolytic T lymphocytes and antibodies to myocytes in adriamycin-treated BALB/c mice. Evidence for immunity to drug-induced antigens.

Authors:  S A Huber; A Moraska
Journal:  Am J Pathol       Date:  1992-01       Impact factor: 4.307

9.  Immunodepressive activity of FCE 23762 on humoral and cell-mediated immune responses in normal mice: comparison with doxorubicin.

Authors:  M C Fornasiero; M Ferrari; P Gnocchi; D Trizio; A M Isetta
Journal:  Agents Actions       Date:  1992-11

Review 10.  Wandering pathways in the regulation of innate immunity and inflammation.

Authors:  Alberto Mantovani
Journal:  J Autoimmun       Date:  2017-10-25       Impact factor: 7.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.